Nifedipin Abz (Nifedipine)

Nifedipine, the active ingredient in Nifedipin Abz, is a calcium channel blocker presented as an oral formulation for oral use. It is employed to manage high blood pressure, relieve chest pain from chronic stable angina, and improve blood flow in Raynaud's phenomenon.\n\nGNH India supplies Nifedipin Abz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nifedipine acts on the cardiovascular system to lower vascular resistance and myocardial oxygen demand.\n\nHypertension: reduces systolic and diastolic blood pressure by relaxing arterial smooth muscle.\nChronic stable angina: decreases frequency of chest pain episodes by improving coronary blood flow.\nRaynaud's phenomenon: alleviates peripheral vasospasm, increasing blood flow to affected extremities.

Nifedipine may cause a range of adverse reactions, from mild to severe.\n\nCommon Side Effects:\n- Headache\n- Flushing\n- Peripheral edema\n- Dizziness or light‑headedness\n- Tachycardia\n- Nausea\n\nSerious or Rare Side Effects:\n- Severe hypotension\n- Myocardial infarction or worsening angina\n- Hepatic dysfunction\n- Allergic reactions such as rash or anaphylaxis\n- Cardiac arrhythmias\n- Blood dyscrasias (e.g., neutropenia, thrombocytopenia)

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.\n\nMonitor blood pressure: adjust therapy if hypotension occurs.\nAssess cardiac function: avoid use in patients with severe aortic stenosis or recent myocardial infarction.\nReview concomitant medications: consider additive effects with other antihypertensives.\nUse caution in hepatic impairment: dose adjustments may be required.\nAvoid abrupt discontinuation: taper to prevent rebound hypertension.\nStore at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Nifedipine can interact with several drug classes, altering its efficacy or safety profile.\n\nMajor Interactions (Avoid):\n- Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) – may increase plasma levels.\n- Grapefruit juice – can markedly raise nifedipine concentrations.\n- Concurrent use with other calcium channel blockers – risk of excessive vasodilation.\n\nModerate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine) – may reduce effectiveness.\n- Diuretics – may enhance hypotensive effect, requiring blood pressure monitoring.